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NeuronOxidative stress and mitochondrial dysfunction are involved in the progression and pathogenesis of multiple
sclerosis (MS).MitoQ is amitochondria-targeted antioxidant that has a neuroprotective role in severalmitochon-
drial and neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Here we sought
to determine the possible effects of a systematic administration of MitoQ as a therapy, using an experimental
autoimmune encephalomyelitis (EAE) mouse model. We studied the beneﬁcial effects of MitoQ in EAE mice
that mimic MS like symptoms by treating EAE mice with MitoQ and pretreated C57BL6 mice with MitoQ plus
EAE induction.We found that pretreatment and treatment of EAEmice withMitoQ reduced neurological disabil-
ities associated with EAE. We also found that both pretreatment and treatment of the EAE mice with MitoQ sig-
niﬁcantly suppressed inﬂammatory markers of EAE, including the inhibition of inﬂammatory cytokines and
chemokines. MitoQ treatments reduced neuronal cell loss in the spinal cord, a factor underlying motor disability
in EAE mice. The neuroprotective role of MitoQ was conﬁrmed by a neuron-glia co-culture system designed
to mimic the mechanism of MS and EAE in vitro. We found that axonal inﬂammation and oxidative stress are
associated with impaired behavioral functions in the EAE mouse model and that treatment with MitoQ can
exert protective effects on neurons and reduce axonal inﬂammation and oxidative stress. These protective effects
are likely via multiplemechanisms, including the attenuation of the robust immune response. These results sug-
gest that MitoQ may be a new candidate for the treatment of MS.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS), an autoimmune demyelinating diseasewith
highly disabling consequences, affects over 2.5 million people world-
wide, especially young people. It is characterized by chronic inﬂamma-
tion and axonal loss in the central nervous system (CNS) [1–5].
The hallmark pathology in MS is inﬂammation of the myelin, the
fatty sheath that insulates nerve cells. The inﬂammation denudes and
scars the myelin, often resulting in permanent damage to the nerves.
The cause of MS is enigmatic, although most investigators believe that
the immune system attacks thewhitematter of brain [6]. Recent studies
have found extensive demyelination in the cerebral cortex, in MS
patients [7–9], even in early stages of disease progression [10]. In active
gray matter lesions, activated microglia were reported to appose and
ensheath apical dendrites, neurites, and neuronal perikarya [11]. Acti-
vated microglia are a major source of cytokines and oxidizing radicals,gon National Primate Research
rsity, 505 NW 185th Avenue,
1 503 418 2701.
ights reserved.e.g., superoxides, hydroxyl radicals, hydrogen peroxide, and nitric oxide
[4,12,13], which have been found to damage cell components.
Further, the extent of lipid andDNA oxidation correlated signiﬁcantly
with inﬂammation in brain lesions of patientswithMS [14].Mechanisms
of axonal degeneration that researchers have proposed in MS include
cytosolic and (subsequent) mitochondrial Ca2+ overload, the accumu-
lation of pathologic reactive oxygen species (ROS), and mitochondrial
dysfunction, any of which could lead to cell death [4,15].
To reducemyelin inﬂammation and subsequent denuding ofmyelin,
researchers have turned to immunomodulatory or immunosuppressive
therapy [16]. However, these treatments are not always successful, and
patients have had severe, adverse effects. IFN-β and glatiramer have
shown therapeutic beneﬁts in about 50%of patientswithMS,whoexpe-
rienced reduced relapse at a rate of about 30%, and a slowed progression
of disability. Although these results are encouraging, especially since the
advancements in treatment have all occurred within years the search
for new compounds to reduce or to prevent autoimmune inﬂammation,
without causing signiﬁcant side effects, continues.
Since ROS has been identiﬁed as being involved in the pathology of
MS in humans and in animal models of MS, an antioxidant therapy
has been proposed to reduce ROS in patients withMS. One such therapy
Table 1
Summary of real-time RT-PCR oligonucleotide primers used in measuring mRNA expres-
sion in inﬂammatory markers between C57BL6 and EAE mice, C57BL6 and MitoQ + EAE
mice, and C57BL6 + EAE + MitoQ treated mice.
Marker DNA sequence (5′-3′) PCR product size
MBP Forward primer ACAGAGACACGGGCATCCTT 56
Reverse primer CACCCCTGTCACCGCTAAAG
CD4 Forward primer AGGGAGAGTCAGCGGAGTTCT 59
Reverse primer CTCCCCACCCGTTTTCCT
CD8 Forward primer CGAAAGCGTGTTTGCAAATG 54
Reverse primer TGGGCTTGCCTTCCTGTCT
CD11b Forward primer AAACCACAGTCCCGCAGAGA 57
Reverse primer CGTGTTCACCAGCTGGCTTA
CD11C Forward primer CCTGAGGGTGGGCTGGAT 50
Reverse primer GCCAATTTCCTCCGGACAT
IL1 Forward primer CCATGGCACATTCTGTTCAAA 55
Reverse primer GCCCATCAGAGGCAAGGA
IL6 Forward primer CCACGGCCTTCCCTACTTC 60
Reverse primer TTGGGAGTGGTATCCTCTGTGA
IL10 Forward primer GATGCCCCAGGCAGAGAA 58
Reverse primer CACCCAGGGAATTCAAATGC
IL17 Forward Primer CCTGGCGGCTACAGTGAAG 56
Reverse primer TTTGGACACGCTGAGCTTTG
TGFβ Forward primer AGAGCTCGAGGCGAGATTTG 62
Reverse primer TTCTGATCACCACTGGCATATGT
TNFα Forward primer TTCGGCTACCCCAAGTTCAT 55
Reverse primer CGCACGTAGTTCCGCTTTC
STAT3 Forward primer CCCGACAGTGAAGTGGCTACTA 58
Reverse primer TTCCCTAGCGGGCACATG
NOS Forward primer GGATCTTCCCAGGCAACCA 60
Reverse primer CAATCCACAACTCGCTCCAA
NFkB Forward primer CCAGCTTCCGTGTTTGTTCA 63
Reverse primer AGGGTTTCGGTTCACTAGTTTCC
Beta actin Forward primer ACGGCCAGGTCATCACTATTC 65
Reverse primer AGGAAGGCTGGAAAAGAGCC
GAPDH Forward primer TTCCCGTTCAGCTCTGGG 59
Reverse primer CCCTGCATCCACTGGTGC
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is conjugated to triphenylphosphonium cation [17]. MitoQ has been
found to promote the uptake of CoQ10 into mitochondria in a cell and
animal model of Alzheimer's disease and in ischemia, where it was
found to combat ROS originating in mitochondria [17,18]. Several re-
searchers reported that MitoQ has an anti-oxidant role in vitro [18]
and in vivo [17]. In addition, when high levels of MitoQ orally were
given to wild-type mice (C57BL/6 strain) or up to 28 weeks, the mice
exhibited no measurable adverse effects [19]. However, the effects of
MitoQ in animal models of MS or in patients with MS have not yet
been investigated.
In the current study, we studied the effects ofMitoQ on the develop-
ment and progression of an experimental autoimmune encephalomy-
elitis (EAE) mouse model, the most widely used animal model of MS.
We also investigated the possible underlying mechanisms of MitoQ in
the EAE mouse model.
2. Material and methods
2.1. EAE mouse model
Ten-week-old -old C57BL/6 mice (25 to 35 g) were purchased from
Taconic Farms (New York, NY) and housed in the animal facility of the
Oregon National Primate Center at Oregon Health & Science University
(OHSU). We used these mice for EAE induction and MitoQ treatments.
The OHSU Institutional Animal Care and Use Committee approved all
procedures for animal care according to guidelines set forth by the Na-
tional Institutes of Health.
We studied 4 groups of mice (10 mice in each group): 1. Normal
control mice - C57BL6 strain, 2. EAE mice (vehicle treated), 3. MitoQ
pretreated/EAE mice and 4. EAE mice for 1) clinical course of EAE, 2)
mRNA expression of inﬂammatory, apoptotic and oxidative stress
genes in tissues from spinal cord, and 3) immunohistochemistry of the
spinal cords.
2.2. MOG induction
EAE induction was performed as described previously [20,21]. The
C57BL6 mice were injected at ~10 weeks of age with 200 μg MOG
peptide amino acids 35–55 in complete Freund's adjuvant (CFA) with
Mycobacterium tuberculosis H37RA. MOG peptides were mixed with
the adjuvant to yield a 1 mg/ml emulsion of the antigen and of CFA.
As an immunization, 2 × 100 μl emulsion was delivered subcutaneous-
ly to each mouse at two different sites in the trunk. Pertussis toxin
(400 ng/mouse) was injected twice intra-peritoneal (i.p.), in 500 μl
PBS at the time of the immunization and 72 h later. To understand
behavioral changes in the progression of EAE in mice, we scored the
behavioral deﬁcits daily for all mice, using the following 5-point behav-
ioral scoring scale: Grade 0, normal (no clinical signs of EAE); Grade 1,
ﬂaccid tail; Grade 2, mild hindlimb weakness (fast righting reﬂex);
Grade 3, severe hindlimb weakness (slow righting reﬂex); Grade 4,
hindlimb paralysis; Grade 5, hindlimb and forelimb weakness or paral-
ysis, moribundity, or death.
2.3. Treatment of EAE mice with MitoQ
In the preventive treatment group ofmice, we injected vehicle (PBS)
or MitoQ (100 nmol/mouse, i.p. injection) 10 days before immuniza-
tion with MOG and continued treating mice with MitoQ or vehicle for
another 30 days, twice a week (total treatment days 40) (pretreatment
with MitoQ). In therapeutic group of mice, we injected EAE mice with
vehicle or MitoQ (100 nmol/mouse, i.p. twice a week) 14 days after
we induced them with MOG, and we continued treating them with
MitoQ for total 30 days (therapeutic treatment after disease onset). The
duration of treatment – for pre- and post-EAE – is standard and accept-
able to determine MitoQ protective effects against EAE in mice.We determined 100 nmole per mouse i.p. injection twice per week,
based on our earlier preliminary study. Brieﬂy, we tested 2 doses of
MitoQ in 2-month-old C57BL6 mice (n = 6 for each dose), one with
100 nmole per mouse i.p. and the other with 2 μmol per mouse
i.p., twice per week for 3 weeks. In a higher dose (2 μmol per mouse
i.p., twice per week), one mouse became sick, in contrast to the mice
on low dosage of MitoQ, all of which were active and healthy for
3 weeks. Therefore, we chose 100 nmole per mouse i.p. twice per
week for our experimental groups.
2.4. RNA isolation and real-time RT-PCR
Messenger RNA changes of severalMS-associated genes were isolat-
ed from the spinal cord of the non-treated EAE mice and the MitoQ-
treated EAE mice (Table 1). Using primer express software (Applied
Biosystems, Foster City, CA), the oligonucleotide primerswere designed
for β-actin and GAPDH (housekeeping genes) and for MBP, CD4, C8,
CD11b, CD11c, IL1, IL6, IL10, IL17, TGFβ, TNFα, STAT3, NOS, NFkB, and
INFγ. The real-time RT-PCR oligonucleotide primers were designed,
using primer express and primer sequences; amplicon sizes are listed
in Table 1. We measured mRNA expression of the genes mentioned
above, using SYBR-Green chemistry-based quantitative real-time RT-
PCR, as described in Manczak et al. [22] and Reddy et al. [23]. Brieﬂy,
2 μg of DNAse-treated total RNA was used as starting material, to
which we added 1 μl of oligo (dT), 1 μl of 10 mM dNTPs, 4 μl of 5×
ﬁrst strand buffer, 2 μl of 0.1 M DTT, and 1 μl RNAse out. The reagents
RNA, dT, and dNTPs were mixed ﬁrst, then heated at 65 °C for 5 min,
and ﬁnally chilled on ice until the remaining components were added.
The samples were incubated at 42 °C for 2 min, and then 1 μl of Super-
script III (40 U/μl) was added. The samples were incubated again at
42 °C, but for 50 min, at which time the reaction was inactivated by
heating the samples at 70 °C for 15 min.
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unregulated endogenous reference gene in experimental animals and
control animals. The CT-value, described in Manczak et al. [22] and
Reddy et al. [23], is an important quantitative parameter in real-time
PCR analysis. All RT-PCR reactions were carried out in triplicate and
with no template control. The mRNA transcript level was normalized
against β-actin and GAPDH at each dilution. The standard curve was
the normalized mRNA transcript level, plotted against the log-value of
the input cDNA concentration at each dilution. Brieﬂy, the comparative
CT method involved averaging triplicate samples, which were taken
as the CT values for β-actin, GAPDH, and mitochondrial genes. β-actin
normalization was used because β-actin and CT values were similar
for mitochondrial structural genes, and also it allows us to avoid the
values of GAPDH. The ΔCT-value was obtained by subtracting the aver-
age β-actin CT value from the average CT-value for the mitochondrial
structural genes. The ΔCT of the controls was used as the calibrator.
The fold change was calculated according to the formula 2−(ΔΔCT
),
where ΔΔCT is the difference between ΔCT and the ΔCT calibrator value.2.5. Histochemistry and quantiﬁcation of inﬂammatory responses
To determine the protective effects of MitoQ in microglial activity
and oxidative stress, we used immunohistochemistry and immunoﬂuo-
rescence analyses of several selective cytokine markers that are differ-
entially expressed in EAE mice. All mice that were used to examine
behavioral analyses were sacriﬁced by cervical dislocation, and then
the spinal cord was frozen quickly and histological examinations were
conducted in the spinal cord. Brieﬂy, we ﬁxed the fresh-frozen tissues
by dipping them into a 4% paraformaldehyde solution for 10 min at
room temperature. The sectionswere incubated overnight at room tem-
perature with cytokine antibodies. Details of antibodies are given in
Table 2. On the next day, the sections were incubated with the second-
ary antibody conjugatedwith HRP or biotin-labeled secondary antibody
for 1 h. Spinal cord sections were incubated with tyramide-labeled or
streptavidin-conjugated ﬂuorescent dye, Alexa 488 (green) (Molecular
Probes, Eugene, OR). Photographs of spinal cord were taken with a ﬂuo-
rescence microscope.
To quantify the immunoreactivity ofmicroglialmarkers Iba1 and IL6,
and neuronal marker NeuN for each animal, ten sections from each
mouse of the spinal cordwere stained (as described above), and the im-
munoreactive signals were quantiﬁed. From immunostained sections,
several photographs were taken at 10× and 40× (the original) magniﬁ-
cation of the spinal cord. Positive immunoreactive ﬂuorescence signal
intensity of microglia was measured using the red–green and blue
(RGB) method, as described in Manczak et al. [22] and Reddy et al.
[24]. The signal intensity of immunoreactivity for several randomly se-
lected images of each mouse was quantiﬁed, and statistical signiﬁcance
was assessed for each marker in the EAE mice, MitoQ-pretreated,
MitoQ-treated (therapeutic) mice, and normal control mice.Table 2
Summary of antibody dilutions and conditions used in the immunohistochemistry/immunoﬂu
Marker Primary antibody — species and dilution Purchased from company, state S
Iba1 Mouse monoclonal 1:200 Abcam,
Cambridge, MA
G
B
(1
T
IL-6 Rabbit polyclonal 1:200 Abcam,
Cambridge, MA
G
B
(1
T
NeuN Mouse monoclonal 1:200 EMD—Millipore,
Billerica, MA
G
B
(1
T2.6. Co-culture of cortical neurons and microglia
Cortical neurons from wild-type mice (C57BL6; embryonic day 18
[E18]) were plated at 1 × 105 cells/well on poly-D-lysine-coated 24-
well plates in a neurobasal medium (Invitrogen, San Diego, CA, USA)
containing a supplement of 2% B-27 and 0.6 mM L-glutamine. The
cells were incubated in humidiﬁed air of 5% CO2 [21,25,26]. Microglia
from the BV2 cell line (American Type Culture Collection, Manassas,
VA, USA) were cultured in RPMI 1640 (Invitrogen) supplemented
with 10% heat-inactivated FBS and 1% penicillin/streptomycin. The
cells were then cultured in humidiﬁed air containing 5% CO2. Twenty-
four hours after the plating, MitoQ (40 nM ﬁnal concentration) was
added to the neuronal culture from the treatment groups. After another
24 h, microglia (1 × 105 cells/well) were seeded with primary neuro-
nal cultures. At this point, the medium containing MitoQ was removed
from the “pretreatment” plates and stimulated with 1 μg/ml lipopoly-
saccharide for 60 h. Cells were subjected to a 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or ﬁxed with 4%
paraformaldehyde for 20 min and stainedwith a NeuN/β3-tubulin anti-
body (Covance, Princeton, NJ, USA; 1:500) and a proper second anti-
body. The numbers of NeuN/β3-tubulin-positive cells were quantiﬁed
in triplicate in three independent experiments.
2.7. Statistical analysis
Data were expressed as the mean ± SEM, except where otherwise
indicated. Data were compared using ANOVA and Student's t-test with
SigmaStat 3.5 software; P b 0.05was considered statistically signiﬁcant.
3. Results
3.1. Reduction of neurological disability in the MitoQ-treated EAE mice
To determine the possible role and mechanisms of MitoQ therapy
administered to an EAEmousemodel ofMS, we ﬁrst examinedwhether
MitoQ affects behavioral deﬁcits associated with a chronic form of EAE:
forelimb and hindlimb paralysis. We followed a standard procedure to
induce EAE by immunizing wild-type (C57BL6) mice with MOG.
Consistent with previous reports [20,21,27,28], our vehicle-treated
EAE mice developed a typical course of EAE neurological disability,
which became obvious around two weeks after immunization. The dis-
abilities persisted for at least 8 weeks (Fig. 1). However, our EAE mice
that were pretreated with MitoQ showed a modest but statistically
signiﬁcant delay in the onset of behavioral deﬁcits (Fig. 1A), as well
as an attenuation of symptoms over the course of EAE development
(Fig. 1A, P b 0.05). Interestingly, EAE mice that received MitoQ treat-
ment (after day 12 i.p.) had received signiﬁcantly reduced scores for
their symptoms (Fig. 1B). These ﬁndings point to a protective role for
MitoQ in the EAE mouse model.orescence analysis in EAE mouse.
econdary antibody, dilution, Alexa ﬂuor dye Purchased from company, city & state
oat anti-mouse
iotin 1:300, HRP-Streptavidin
: 100),
SA-Alexa488
KPL, Gaithersburg, MD
Vector Laboratories Inc., Burlingame, CA
Molecular Probes, Eugene, OR
oat anti-rabbit
iotin 1:300, HRP-Streptavidin
: 100),
SA-Alexa488
KPL, Gaithersburg, MD
Vector Laboratories Inc., Burlingame, CA
Molecular Probes, Eugene, OR
oat anti-mouse
iotin 1:300, HRP-Streptavidin
: 100),
SA-Alexa488
KPL, Gaithersburg, MD
Vector Laboratories Inc., Burlingame, CA
Molecular Probes, Eugene, OR
Fig. 1. MitoQ treatments modestly delayed the onset and signiﬁcantly attenuated the behavioral deﬁcits of EAE. EAE was induced, disease activity was monitored daily, and the mean
EAE score was calculated for vehicle-treated (ﬁlled squares, n = 10), Mito-Q pretreated, and Mito-Q EAE mice and normal control mice (ﬁlled diamonds, without MOG immunization,
n = 10). The results shown are representative of 3 separate experiments.
Table 3
mRNA expression fold change in inﬂammatory genes of EAE mice, MitoQ pretreated EAE
mice, EAE mice treated with MitoQ relative to control, wild-type mice.
Gene Control mice versus EAE mice, MitoQ pretreated + EAE mice
and EAE mice treated with MitoQ Spinal cord
EAE mice MitoQ + EAE mice EAE + MitoQ mice
MBP −2.7 −1.3 −1.5
CD4 2.8 −2.4 −3.0
CD8 2.5 −1.7 −5.7
CD11b 2.6 −6.5 −5.2
CD11c 1.3 1.2 1.4
IL1 3.0 −5.4 −6.0
IL6 2.6 −5.1 −6.0
IL10 1.8 −6.4 −10.2
IL17 1.8 −2.5 −7.4
TGFβ 2.0 2.4 1.2
TNFα 1.7 −1.9 −2.5
STAT3 1.4 2.5 3.2
NOS 2.8 −8.3 −7.9
NFkB 1.4 −1.8 −2.6
INFγ 6.5 5.1 2.8
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mice
To determine the effects of MitoQ on EAE mice, we prepared RNA
from spinal cords of control C57BL6 mice, MitoQ + EAE mice, and
EAE + MitoQ mice. We compared gene expression levels, using real-
time RT-PCR analysis, and we measured mRNA levels of genes that are
associated with central nervous system inﬂammation, including MBP,
CD4, CD8, CD11b, CD11c, IL1, IL6, IL10, IL17, TGFβ, TNFα, STAT3, NOS,
NFkB, and INFγ.
3.2.1. MBP (myelin basic protein)
Comparing mRNA levels of MBP in EAE-induced C57BL6 mice with
C57BL6 mice, we found mRNA expression levels decreased in MBP
by 2.7 fold. However, mRNA expression levels were decreased in the
MitoQ + EAE mice and EAE + MitoQ-treated mice relative to the
C57BL6 mice (Table 3). These ﬁndings suggest that MitoQ treatment
increases MBP expression in EAE mice.
3.2.2. CD4, CD8 and CD11b
As shown in Table 3, mRNA analysis of the spinal cords of EAE mice
compared to the spinal cords of C57BL6 mice showed mRNA expres-
sions levels increased in CD4 by 2.8 fold, in CD8 by 2.5 fold, and in
CD11b by 2.6 fold, indicating that EAE induce enhance inﬂammatoryresponse genes. In contrast, in the MitoQ-pretreated plus EAE-induced
C57BL6 mice relative to the C57BL6 mice, mRNA levels were decreased
in CD4 by 2.4 fold, in CD8 by 1.7 fold, and in CD11b by 6.5 fold. Similarly,
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fold, in CD8 by 5.7 fold, and in CD11b by 5.2 fold (Table 3). These ﬁnd-
ings suggest that MitoQ markedly reduces inﬂammatory markers in
the spinal cords of EAE mice.
3.2.3. CD11c
mRNA levels of CD11c did not change in the EAE-induced mice
relative to the C57BL6 mice (the difference was 1.3 fold) and also
MitoQ + EAE mice (the difference is 1.2 fold) and EAE + MitoQ mice
(the difference is 1.3) relative to C57BL6 mice (Table 3).
3.2.4. IL1, IL6, IL10 and IL17
As shown in Table 3, in the spinal cords of EAE-induced C57BL6mice
compared to the spinal cords of C57BL6 mice, mRNA expressions levels
were increased in IL1 by 3.0 fold, in IL6 by 2.6 fold, in IL10 by 1.8 fold,
and in IL17 by 1.8 fold, suggesting that the inducement of EAE enhances
inﬂammatory-response genes (Table 3). However, in theMitoQ-treated
plus EAE-induced C57BL6 mice relative to C57BL6 mice, mRNA levels
were decreased in IL1 by 5.4 fold, IL6 by 5.1 fold, IL10 by 6.4 fold, and
IL17 by 2.5 fold. Similarly, mRNA levels in the therapeutic mice
(EAE + MitoQ) were reduced in IL1 by 6.0 fold, IL6 by 6.0 fold, IL10
by 10.2 fold, and IL17 by 7.4 fold. These ﬁndings indicate that MitoQ can
markedly reduce inﬂammatory markers in the spinal cords of C57BL6
mice with EAE.
3.2.5. TNFα
Research in MS has revealed that TNFα is elevated in MS brains and
in the spinal cords of EAE mice. To determine the effects of MitoQ
on EAE mice, we studied mRNA levels in C57BL6 mice, MitoQ + EAEFig. 2. Quantitative immunostaining analysis of Iba1 in the spinal cords of normal control C57B
noreactivity of Iba1— images A& E from controlmice; images B& F fromEAEmice; C &G fromM
in 10× original magniﬁcation and E to H in 40× original magniﬁcation. Panel B indicates quanmice, and EAE + MitoQ treated mice. As shown in Table 3, TNFα
mRNA levels were upregulated by 1.7 fold in the EAE mice relative
to the C57BL6 mice. However, mRNA expression was reduced in the
MitoQ + EAE mice by 1.9 fold and in the EAE + MitoQ mice by 2.5
fold (Table 3). These observations suggest that MitoQ can suppress
inﬂammation in EAE mice.
3.2.6. NOS2, NFkB
Similar to other inﬂammatory markers, the mRNA levels of NOS2,
NFkB in the EAE mice relative to the control C57BL6 mice were up-
regulated in NOS2 by 2.8 fold and inNFkB by 1.4 fold. These upregulated
mRNA levelswere reduced for NOSby 8.3 fold in theMitoQ + EAEmice
and 7.9 fold in the EAE + MitoQ mice relative to C57BL6 mice. mRNA
levels of NFkB were also down-regulated in the MitoQ + EAE mice by
1.8 fold and in the EAE + MitoQ by 2.6 (Table 3).
3.2.7. STAT3
In STAT3, an anti-apoptotic gene, mRNA levels were upregulated by
1.4 fold in the EAE mice relative to the control C57BL6 mice. Unlike
other inﬂammatory markers, STAT 3 mRNA levels were upregulated in
the MitoQ + EAE mice and in the EAE + MitoQ-treated mice relative
to the control C57BL6 mice (Table 3), indicating that MitoQ enhances
STAT3 levels. STAT3mayhave someprotective, beneﬁcial effects against
EAE in mice.
3.3. Immunohistochemistry analysis — Iba1
Using immunohistochemistry analysis of spinal cord sections from
all 4 groups of mice, we aimed to ascertain the treatment effects ofL6 mice, EAE mice, MitoQ + EAEmice and EAE + MitoQmice. Panel A represents immu-
itoQ-pretreated plus EAEmice andD&H fromEAEmice treatedwithMitoQ. ImagesA to D
tiﬁcation of Iba1 immunoreactivity.
2327P. Mao et al. / Biochimica et Biophysica Acta 1832 (2013) 2322–2331MitoQ on inﬂammation and demyelination. We used a speciﬁc marker,
Iba1 antibody for immunostaining of glial cells in the spinal cord be-
cause active glial cells are the main source of inﬂammation factors,
such as pathological cytokines and ROS. Compared to normal control
C57BL/6 mice (Fig. 2A and E), EAE mice (Fig. 2B and F) showed signiﬁ-
cantly high levels of Iba1 immunoreactivity (P = 0.001), indicating
strong inﬂammation in their spinal cords (Fig. 2). Compared to the
vehicle-treated EAE mice (Fig. 2B, images B and F), both MitoQ groups –
the pretreated (Fig. 2C and G; P = 0.01) the MitoQ-treated EAE mice
(Fig. 2D and H; P = 0.03) – showed signiﬁcantly reduced Iba1 immuno-
reactivity (Fig. 2), indicating MitoQ reduced CNS inﬂammation.
3.4. Immunohistochemistry analysis — IL6
Interleukin-6 (IL6) plays critical roles in the pathogenesis of auto-
immune diseases, including EAE [29]. Importantly IL6-deﬁcient mice
(IL6 KO) were resistant to MOG-induced EAE [30]. Also, IL6 could cause
typical or atypical EAE in such IL6 KO mice [31,32]. Further, inhibition of
IL6 production alleviated pathogenesis of EAE [33]. Hence we selectively
examined the protein expression for IL6 in the spinal cord. Interestingly,
the changes in the RNA expression of the spinal cord IL6 (Table 3) were
conﬁrmed by immunoreactivity of IL6 (Fig. 3). Compared to normal con-
trol mice (Fig. 3A and E), EAE mice showed signiﬁcantly increased levels
of IL6 immunoreactivity (Fig. 3B and F; P = 0.003), indicating elevated
inﬂammation in their spinal cords of EAE mice. Compared to EAE mice
(Fig. 3B and F), both the MitoQ-pretreated EAE mice (Fig. 3C and G;
P = 0.01) and MitoQ-treated EAE mice (Fig. 3D and H; P = 0.01)
showed signiﬁcantly reduced IL6 immunoreactivity, indicating thatFig. 3. Quantitative immunostaining analysis of IL6 in the spinal cords of normal control C57BL
noreactivity of IL6— images A&E fromnormal controlmice; images B& F fromEAEmice; C &G
A to D in 10× original magniﬁcation and E to H in 40× original magniﬁcation. Panel B indicateMitoQ suppressed inﬂammation in EAE mice and the densities of their
white matter cells were similar to those of the normal control mice.
3.5. MitoQ protective effects against neurodegeneration in EAE
mice – Immunostaining analysis of neuronal marker – NeuN
In light of the profound anti-inﬂammatory effects that appeared to
be induced byMitoQ treatments of EAEmice (Table 2; Fig. 1),we sought
to determine whether these effects correlated with the preservation
of neuronal cells. Our initial histological analysis indicated that the
most severe neuronal damage was most frequently in the lumbar
spinal cord sections (data not shown), consistent with previous studies
[27,34,35]. We did not ﬁnd a signiﬁcant difference between the MitoQ-
pretreated and MitoQ-treated mice in terms of neuroprotection. We
then focused on sections from the lumbar spinal cord of EAE, EAE-
treatedwithMitoQ, and normal controlmice, using immunohistochem-
istry with an antibody against NeuN.
Immunostaining results are shown in Fig. 4. We observed a signiﬁ-
cant difference in the extent of neuronal loss across thesemouse groups.
Within the spinal cord of EAE mice, signiﬁcantly reduced positively
labeledwith anti-NeuN antibody (Fig. 4B and F), compared to the spinal
cord neurons from the normal control mice (Fig. 4A and E). However,
we found signiﬁcantly increased staining of anti-NeuN in the spinal
cord sections from the MitoQ-pretreated EAE mice (Fig. 4C and G) and
EAE mice treated with MitoQ (Fig. 4D and H). In addition, we did not
ﬁnd a signiﬁcant difference between the MitoQ-pretreated and the
MitoQ-treated EAE mice in terms of neuroprotection. Quantiﬁcation of
NeuN positive cells in the spinal cord conﬁrmed signiﬁcant neuronal6 mice, EAE mice, MitoQ + EAE mice and EAE + MitoQ mice. Panel A represents immu-
fromMitoQ-pretreatedplus EAEmice andD&H fromEAEmice treatedwithMitoQ. Images
s quantiﬁcation of IL6 immunoreactivity.
Fig. 4.Quantitative immunostaining analysis of neuronalmarker—NeuN in the spinal cords of normal control C57BL6mice, EAEmice,MitoQ + EAEmice and EAE + MitoQmice. Panel A
represents immunoreactivity of NeuN— images A & E from control mice; images B & F from EAEmice; C & G fromMitoQ-pretreated plus EAEmice and D & H from EAEmice treatedwith
MitoQ. Images A to D in 10× original magniﬁcation and E to H in 40× original magniﬁcation. Panel B indicates quantiﬁcation of NeuN immunoreactivity.
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mice, whereas the MitoQ-pretreated mice and EAE mice treated with
MitoQ had NeuN positive cell numbers that were no different from
numbers in the normal control mice. These data suggest that MitoQ
treatment is primarily responsible for preserving demyelinated axons
and neurons in the EAE mouse model. To further understand this key
role of neuroprotection, we studied an in vitro EAE mouse model of
MS, in which there are only two kinds of brain cells: mouse primary cul-
tured neurons and microglial cells.
3.6. MitoQ treatment attenuates neuronal damage in
lipopolysaccharide-activated microglia in vitro
To determine whether MitoQ protects against axonal damage
triggered by inﬂammation, we used an in vitro model of microglia-
mediated neurotoxicity [21,36]. As shown in Fig. 5A, cell survival was
signiﬁcantly reduced when cells were exposed to lipopolysaccharide.
In the exposure of these cells to lipopolysaccharide-activatedmicroglia,
MitoQ treatment prevented cell death and increased cell survival, as
determined by an MTT assay. This protective effect was obvious even
when MitoQ was used only as a pretreatment to neurons before neu-
rons were co-cultured with activated microglia. Speciﬁcally, in this co-
culture, the number of Tuj-1 -positive cortical neurons decreased after
they were exposed to lipopolysaccharide-activated microglia (Fig. 5B
and 5C). The treatment of neuronswithMitoQ attenuated theneurotox-
icity triggered by lipopolysaccharide-activatedmicroglia. Thus, together
with the in vivo immunostaining data shown in Fig. 4, these results sug-
gest that MitoQ therapy plays a neuroprotective role that may underlie
protection against mitochondrial oxidative damage in EAE.4. Discussion
Using an EAE mouse model of MS, we found that the pretreatment
and treatment of EAEmicewithMitoQ reduced axonal loss and reduced
neurological disabilities associated with EAE, suggesting a previously
unrealized neuroprotective role for MitoQ. MitoQ also signiﬁcantly
reduced neuronal inﬂammation and demyelination, and increased and
preserved axons in EAE lesions, all of which support the possibility
that MitoQ treatment can protect demyelinated axons from additional
degeneration. The extent of axonal protection correlatedwith neurolog-
ical scores from these groups supporting a critical contribution of axonal
damage to EAE-associated behavioral deﬁcits.
MitoQ consists of a lipophilic cation, triphenylphosphonium, at-
tached to ubiquinone by a saturated 10-carbon alkyl chain. Once inside
the mitochondria, ubiquinone is reduced to its active ubiquinol form
by Complex II [37–40]. Mechanistically, the lipophilic cation is attached
to antioxidants, such as vitamin E and coenzyme Q. These lipophilic
cations attached antioxidants were preferentially taken up by mito-
chondria due to a charge difference betweenmitochondria (with a neg-
ative charge) and lipophilic cation-based antioxidants (with a positive
charge). These antioxidants accumulate ﬁrst in the cytoplasm of cells,
due to a negative plasma membrane potential. They later enter mito-
chondria and accumulate several hundred fold within themitochondrial
matrix [40]. They then rapidly scavenge free radicals in themitochondria
and protect mitochondria and cells from oxidative insults. It has been
shown that MitoQ has a protective role in animal and cell models of sev-
eral human disease, including Parkinson's disease [41] and Alzheimer's
disease [18,42,43]. Our current study is theﬁrst to investigate the efﬁcacy
of MitoQ in an experimental mouse model of MS.
Fig. 5. MitoQ attenuated neurotoxicity induced by lipopolysaccharide-activated microglia. A. MTT assay. Cultured neurons with microglia (ﬁrst bar, without lipopolysaccharide), with
lipopolysaccharide stimulated microglia (second bar), with lipopolysaccharide-stimulated microglia plus 40 nM MitoQ, pretreatment only (third bar), and with lipopolysaccharide-
stimulatedmicroglia plus 40 nMMitoQ (fourth bar). Statistical analysis was done by oneway ANOVA. MitoQ treatment (both pretreatment alone and continuous, P b 0.05) signiﬁcantly
preserved neurons co-cultured with lipopolysaccharide-activated microglia. B. Representative images showing neuron–microglial co-cultures in different conditions, in phase contrast
lightmicroscopy. Images show culturedneuronswithmicroglia (BV2)without lipopolysaccharide stimulation (ﬁrst column),with lipopolysaccharide (second column), andwith lipopoly-
saccharide plus 40 ng mitoQ (third column). C. Tuj-1-positively stained neurons under different conditions. MitoQ continuous treatment reduced neuronal death induced by co-culture
with lipopolysaccharide-activated microglia.
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mental mouse models of MS and for humans with MS. To our knowl-
edge, the longest-term animal study with MitoQ involved regularly
feeding rats (with cardiac ischemia–reperfusion injury) with drinking
water that contained a higher dose of MitoQ (500 μM) [44]. The sub-
sequent study also treated 3xAD Tg. mice with MitoQ in drinking
water, but at 100 μM [43]. Similarly, Wani et al. [45] used MitoQ
at 100 μmol/kg (100 nmol/g) via an intragastric method for rats. These
MitoQ-treated animals exhibited beneﬁcial effects, indicating that a dos-
age between 100–500 μMwas safe and well-tolerated in drinking water.
The method of i.p. injection is a convenient way to deliver MitoQ in
many in vivo studies; however, we have found no reports using i.p. todeliver MitoQ except for our current study. As mentioned in Methods,
we used MitoQ i.p. at100 nmol/mouse (~30 g), twice per week for sev-
eral weeks in our in vivo EAE mouse study. We found the 100 nmole
dosage is safe and tolerable, and our EAE mice also exhibited robust
beneﬁcial effects in terms of the reduction of inﬂammation and neuro-
nal loss in their spinal cords.
The cause and the pathology of MS, especially triggers that lead
to axonal destruction, are still unclear. Axonal damage could result
from cytotoxic T lymphocytes or soluble inﬂammatory mediators
directly launching an immunologic attack on axons [46], or MS-
related axonal damage could be a secondary event to inﬂammatory
demyelination [47]. Genetic weakness, mitochondria dysfunction,
2330 P. Mao et al. / Biochimica et Biophysica Acta 1832 (2013) 2322–2331oxidative stress, and ion imbalance may also play an important role
in MS pathogenesis [4].
Microglia are major source of ROS and inﬂammatory cytokines, as
mentioned above. Notably, ROS is required for the phagocytosis of
myelin by macrophages/microglia. Further, increased ROS has been
found to be a novel therapeutic strategy that results in reduced
neuroinﬂammation in MS [48,49]. Further, mitochondria are the main
source of ROS; hence, mitochondria-targeted antioxidants, such as
MitoQ, are promising candidates for the treatment of diseases involving
neuroinﬂammation, such as MS.
In the study reported here, MitoQ therapy reduced axonal degener-
ation in the EAE model, suggesting this axonal damage may be mecha-
nistically related to oxidative damage found in the CNS of patients with
MS. Thus, in EAE and MS lesions, demyelinated axons, no matter their
cause, may become vulnerable to damage by such inﬂammatory medi-
ators as proteolytic enzymes, cytokines, free radicals, and oxidative
products that result from activated immune and glial cells, as proposed
previously [50,51]. Therefore, a treatment that effectively changes this
inﬂammatory pathology may hold therapeutic promise for patients
with MS.
How does MitoQ protect axons from degeneration? Our previous
results [18] indicated that the addition ofMitoQ in a cultured neuroblas-
toma cells that were treated with an amyloid beta peptide decreased
free radicals and increased the energy metabolism of neurons, ulti-
mately leading to neuronal survival. In the current study, we also
found that MitoQ attenuated neuronal toxicity that was induced by
lipopolysaccharide-activated microglia, consistent with recent obser-
vations that mitochondrial dysfunction and energy failure may be a
cause of axonal degeneration in patients withMS [4,52,53]. However, in-
creased mitochondrial content has been found in remyelinated axons
[54]. Thus, both pretreatment and treatment administration of MitoQ
could improve the local bioenergetics of the affected neurons in EAE
mice and protect axons fromdegeneration. Interestingly, some patholog-
ical cytokines, such as IL6 and inﬁltrated microglial cells, were found to
be decreased in the MitoQ treated EAE mice. In agreement with our
study, treatment of rats with MitoQ reduced IL6 and oxidative stress,
and improved mitochondrial function [55]. In light of ample evidence
suggesting that axonal degeneration could trigger responses of microglia
(andmicrophage) [56], axonal degeneration may lead to microglial inﬁl-
tration and activation, which may also affect the extent of axonal loss in
EAE models.
Efforts have been made to research the possible neuroprotective
effects of a variety of agents, including cytokines, growth factors, and
blockers of voltage-gated sodium channels, in EAE models [50,51]. Our
current results suggest that MitoQ is a novel, potential therapy that
may protect against oxidative degeneration, thus preventing axonal
damage in EAE models and, ultimately, in patients with MS. The ob-
served correlations between MitoQ and the increase in MBP levels, the
prevention of axonal and neuronal damage, and the alleviation of
behavioral deﬁcits, in particular, may prevent the decline of ATP levels
in neuronal cells from degeneratively diseased animals [17,18,57]. Fur-
ther, MitoQ may also confer a profound, protective effect on axonal
and neuronal degeneration in EAE models. Although we cannot
rule out other possibilities, the protective effects of MitoQ on neu-
rons and other cells, perhaps, oligodendrocytes, reﬂect the inﬂuence of
different oxidant–ATP levels resulting fromMitoQ treatment. The extent
of this inﬂuence may relate to the sensitivities that neurons and non-
neuronal cells may have to the cellular ATP levels.
MitoQ can readily cross the blood–brain barrier, and plasma and
mitochondria membranes [17], making MitoQ additionally attractive
as a promising neuroprotective treatment for patients withMS. Further,
we found that MitoQ regulates some key inﬂammatory-associated
genes, including NOS in the CNS of EAE mice. Better understanding
the homeostatic regulation of neuronal oxidant–ATP levels may allow
us to design ways to further enhance the protective effects of MitoQ
for EAE, MS, and other diseases associated with axonal degeneration.Acknowledgments
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